New diabetes drug shows promise in early trial
NCT ID NCT01022112
First seen Jan 11, 2026 · Last updated Jun 22, 2026 · Updated 25 times
Summary
This Phase 2 trial tested an experimental pill called TA-7284 in 383 adults with type 2 diabetes. The drug works by helping the kidneys remove extra sugar from the body through urine. Researchers compared four different doses of TA-7284 against a placebo to see how well it lowers blood sugar and whether it is safe. The study is complete, and results will show if this drug could become a new treatment option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research site
Chugoku, Japan
-
Research site
Kanto, Japan
-
Research site
Kinki, Japan
-
Research site
Kyushu, Japan
-
Research site
Shikoku, Japan
-
Research site
Tōhoku, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TA-7284 (an SGLT2 inhibitor drug that helps lower blood sugar by making the kidneys remove extra sugar through urine)
What this could lead to
If successful, this could lead to a new oral medication option for managing blood sugar in type 2 diabetes.
What could go wrong
This is a Phase 2 dose-ranging study, so it is still early. The drug may not prove effective enough or could have side effects. Results may not apply to all diabetes patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.